Of 104 studies of provide chain points with dozens of medication, significant shortages have been 40% much less more likely to happen in Canada than within the U.S., a brand new examine discovered, and the distinction was largely attributed to the method taken by the Canadian authorities to the issue.
Between 2017 and 2021, regulators within the U.S. and Canada obtained the identical variety of studies about precise or potential shortages for a similar 96 medicines. Inside a yr, 49% of the 104 associated studies obtained by the U.S. Meals and Drug Administration have been related to a significant scarcity, however solely 34% of the studies for a similar medicine filed with Well being Canada reached that stage, in keeping with the examine printed in JAMA.
The examine additionally discovered that, after combining studies of provide chain points from each the U.S. and Canada, the scarcity threat was almost half for so-called Tier 3 medicines in Canada. This refers to shortages which have the best potential impression on Canada’s drug provide and well being care system. A devoted authorities committee oversees the method for assessing the danger and impression, and for taking motion.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
View All Plans